PDS Biotech appoints Lars Boesgaard as CFO; Matthew Hill resigns effective Dec 1, 2023

PDS Biotechnology Corp

CFO Matthew Hill resigned effective Dec 1, 2023 to pursue other opportunities; no disagreement with company.
Lars Boesgaard appointed CFO effective Dec 4, 2023; brings 25+ years healthcare finance experience.
Employment agreement: $420,000 annual salary, 40% performance bonus, 12-month severance, COBRA reimbursement.
Boesgaard receives inducement option for 200,000 shares vesting over four years.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Matthew Hill

Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer

PDSB · PDS Biotechnology Corp

Effective: 2023-12-01
Successor: Lars Boesgaard
Filed: November 28, 2023, 6:59 PM ET

On November 21, 2023, Matthew Hill submitted his resignation, effective December 1, 2023, as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer of PDS Biotechnology Corporation (the “ Company ”) in order to pursue other professional endeavors.

Appointed

Lars Boesgaard

Chief Financial Officer

PDSB · PDS Biotechnology Corp

Effective: 2023-12-04
Filed: November 28, 2023, 6:59 PM ET

On November 28, 2023, the Company entered into an Executive Employment Agreement with Lars Boesgaard (the “ Employment Agreement ”), pursuant to which Mr. Boesgaard will assume the role of the Company’s Chief Financial Officer, effective as of December 4, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Matthew Hill resigned as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer at PDS Biotechnology Corp.

Action: resigned
Role: Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer

Exact text from the filing

On November 21, 2023, Matthew Hill submitted his resignation, effective December 1, 2023, as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer of PDS Biotechnology Corporation (the “ Company ”) in order to pursue other professional endeavors.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Lars Boesgaard was appointed as Chief Financial Officer at PDS Biotechnology Corp.

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On November 28, 2023, the Company entered into an Executive Employment Agreement with Lars Boesgaard (the “ Employment Agreement ”), pursuant to which Mr. Boesgaard will assume the role of the Company’s Chief Financial Officer, effective as of December 4, 2023.

View on SEC.gov

PDS Biotechnology Corp filing history →

Source: SEC EDGAR

accession 0001140361-23-054768

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.